
|Articles|February 24, 2015 (Updated: April 18, 2020)
- NSCLC (Issue 6)
- Volume 6
- Issue 1
Diagnostic Platforms for Lung Cancer
Author(s)Maria E. Arcila, MD
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
<<<
Articles in this issue
about 11 years ago
Nanovesicles as Targeted Therapy for Lung Cancerabout 11 years ago
Prior Cancer Diagnosis Not Viable Exclusion From Lung Cancer Trialsabout 11 years ago
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizonabout 11 years ago
Lung Cancer Screening: Implementing the New Protocolabout 11 years ago
Maintenance Therapies for Patients with Non-Small Cell Lung Cancerabout 11 years ago
Challenges Oncologists Face in Treating Lung Cancerabout 11 years ago
Potential Modulator of NSCLC Metastasis Identified






























